Vendor Intelligence Report: Junli Peptide

Published 3 Jul 2026. 23-page investigative report on who is behind Junli Peptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 7 Finnrick lab tests, Junli Peptide’s overall record is 6 pass / 1 fail, an 86% pass rate. The record is narrow: every Finnrick sample in this dossier is Retatrutide, so the vendor’s lab signal cannot be generalized to its broader catalog. Retatrutide is the only evidence-backed use case here, and the story is favorable on identity and purity but less reassuring on dosing precision.

The main lab caveat is fill variation. Retained results include both a materially underfilled vial and a materially overfilled vial, and the report shows how Junli’s rating changes when fill is graded more strictly. For buyers, this is not a simple fake-product warning; it is a Retatrutide authenticity signal with a dosing-accuracy constraint.

Outside the vial, the risk profile is structural. Junli presents a trade name, a September 2025 Alibaba Cloud/HiChina domain, and a Shoplaza storefront that was in maintenance mode while online ordering was suspended. The active route shifted to WhatsApp-style sales, with the July capture showing a multi-operator desk rather than a stable checkout path.

The accountability trail remains thin. No legal entity, registration number, or physical address was found in the reviewed site pages, and payment rails include cryptocurrency, Western Union, and T/T. A phone-number cross-reference ties the primary Lisa contact to a Dongguan peptide-sales identity using an English-language alias, while the suspected manufacturer remains only a circumstantial catalog-and-geography lead.

Inside the full report:

  • Complete Retatrutide lab record, fill-precision discussion, and methodology-divergence charts
  • WHOIS, Wayback, Shoplaza, and maintenance-mode storefront timeline
  • Contact-page capture and operator-network analysis for Lisa, Amy, aurora, and the expanded sales desk
  • Phone-number trail linking Junli’s primary contact to a Dongguan peptide-sales Facebook identity
  • Corporate-disclosure, registry-search, payment-rail, and buyer-recourse review
  • Manufacturing-claim analysis, including the Dongguan Chenguang lead and why it remains unconfirmed

Risk assessment

  • Retatrutide dosing-accuracy concern — high: Retatrutide: 7 tests, 6 pass / 1 fail, rating 80.98%, but retained result pages show 18% underfill and 20% overfill; stricter fill methodologies materially reduce confidence.
  • Corporate-accountability concern — high: Junli discloses no legal entity, registration number, or physical address; public searches found no English-language Junli Peptide registry match and operator identities appear as chat-channel aliases.
  • Irreversible-payment and recourse concern — medium: FAQ lists cryptocurrency, Western Union and T/T; with no disclosed legal entity, buyer recourse is weak if funds, shipment, or customs clearance fail.
  • Operational-continuity concern — medium: Domain registered Sept. 5, 2025; storefront was in maintenance mode with online ordering suspended by June 2026 and remained chat-led on July 2, 2026.
  • Injectable-safety verification gap — medium: Retatrutide has only limited captured endotoxin evidence, and no disclosed GMP/FDA/EFSA documentation supports the broader injectable catalog.